Genprex (GNPX) Competitors $0.91 +0.01 (+1.11%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends GNPX vs. OKYO, ANEB, AFMD, OTLK, VRCA, IXHL, SRZN, RAPT, RNXT, and PMNShould you be buying Genprex stock or one of its competitors? The main competitors of Genprex include OKYO Pharma (OKYO), Anebulo Pharmaceuticals (ANEB), Affimed (AFMD), Outlook Therapeutics (OTLK), Verrica Pharmaceuticals (VRCA), Incannex Healthcare (IXHL), Surrozen (SRZN), RAPT Therapeutics (RAPT), RenovoRx (RNXT), and ProMIS Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry. Genprex vs. OKYO Pharma Anebulo Pharmaceuticals Affimed Outlook Therapeutics Verrica Pharmaceuticals Incannex Healthcare Surrozen RAPT Therapeutics RenovoRx ProMIS Neurosciences Genprex (NASDAQ:GNPX) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk. Do institutionals and insiders hold more shares of GNPX or OKYO? 14.1% of Genprex shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 8.5% of Genprex shares are owned by company insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer GNPX or OKYO? In the previous week, Genprex had 2 more articles in the media than OKYO Pharma. MarketBeat recorded 2 mentions for Genprex and 0 mentions for OKYO Pharma. Genprex's average media sentiment score of 0.35 beat OKYO Pharma's score of 0.00 indicating that Genprex is being referred to more favorably in the media. Company Overall Sentiment Genprex Neutral OKYO Pharma Neutral Is GNPX or OKYO more profitable? OKYO Pharma's return on equity of 0.00% beat Genprex's return on equity.Company Net Margins Return on Equity Return on Assets GenprexN/A -409.48% -269.17% OKYO Pharma N/A N/A N/A Which has preferable earnings and valuation, GNPX or OKYO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenprexN/AN/A-$30.86MN/AN/AOKYO PharmaN/AN/A-$16.83MN/AN/A Does the MarketBeat Community favor GNPX or OKYO? Genprex received 191 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 100.00% of users gave OKYO Pharma an outperform vote while only 65.25% of users gave Genprex an outperform vote. CompanyUnderperformOutperformGenprexOutperform Votes19965.25% Underperform Votes10634.75% OKYO PharmaOutperform Votes8100.00% Underperform VotesNo Votes Which has more risk & volatility, GNPX or OKYO? Genprex has a beta of -1.38, meaning that its share price is 238% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500. Do analysts prefer GNPX or OKYO? Genprex presently has a consensus price target of $10.00, suggesting a potential upside of 998.90%. OKYO Pharma has a consensus price target of $7.00, suggesting a potential upside of 560.38%. Given Genprex's higher possible upside, equities analysts clearly believe Genprex is more favorable than OKYO Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryOKYO Pharma beats Genprex on 6 of the 11 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGenprexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.66M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5989.9717.18Price / SalesN/A195.801,116.21116.99Price / CashN/A57.1642.8937.86Price / Book0.185.094.784.78Net Income-$30.86M$151.83M$120.23M$225.60M7 Day Performance-21.55%-2.13%-1.92%-1.23%1 Month Performance-20.18%-3.10%11.49%3.36%1 Year Performance-89.11%11.54%30.57%16.60% Genprex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGenprex3.9233 of 5 stars$0.91+1.1%$10.00+998.9%-89.1%$7.66MN/A0.0020Gap UpOKYOOKYO Pharma1.5665 of 5 stars$1.02-3.8%$7.00+586.3%-38.4%$34.52MN/A0.007Gap DownANEBAnebulo Pharmaceuticals1.9538 of 5 stars$1.33-5.0%$8.00+501.5%-60.7%$34.49MN/A-4.674News CoverageGap UpAFMDAffimed4.451 of 5 stars$2.14-0.5%$13.50+530.8%-73.8%$34.45M$8.95M0.0076Analyst RevisionNews CoverageOTLKOutlook Therapeutics1.8297 of 5 stars$1.43-3.4%$42.34+2,861.0%-83.2%$33.83MN/A0.0020VRCAVerrica Pharmaceuticals4.6589 of 5 stars$0.74-3.3%$9.50+1,191.5%-89.2%$33.54M$5.12M-0.4240Analyst ForecastNews CoverageIXHLIncannex HealthcareN/A$1.86+5.1%N/A-55.1%$32.82M$86,000.00-1.343SRZNSurrozen1.0796 of 5 stars$10.05+2.0%N/A+34.0%$32.66M$10M0.0042RAPTRAPT Therapeutics4.5185 of 5 stars$0.92+1.1%$9.50+932.4%-96.3%$32.17M$1.53M-0.3380RNXTRenovoRx1.2287 of 5 stars$1.24-3.1%$6.50+423.9%+47.1%$29.78MN/A-2.256Positive NewsGap UpPMNProMIS Neurosciences1.0623 of 5 stars$0.90-2.9%N/A-20.0%$29.51M$10,000.00-9.306Positive News Related Companies and Tools Related Companies OKYO Competitors ANEB Competitors AFMD Competitors OTLK Competitors VRCA Competitors IXHL Competitors SRZN Competitors RAPT Competitors RNXT Competitors PMN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNPX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNPX Stock Alerts